Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study

BACKGROUND: Pegylated liposomal doxorubicin (PLD) and epirubicin are both superior variants of doxorubicin and are commonly applied as basic chemotherapeutics in breast cancer. However, the direct comparison of their efficacy and side effects has not been adequately reported. This study aimed to com...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Minjun, Luo, Liang, Ying, Xiaogang, Lu, Xianqiu, Shen, Jianguo, Jiang, Zhinong, Wang, Linbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061676/
https://www.ncbi.nlm.nih.gov/pubmed/30087568
http://dx.doi.org/10.2147/OTT.S162003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061676/
https://www.ncbi.nlm.nih.gov/pubmed/30087568
http://dx.doi.org/10.2147/OTT.S162003

Ejemplares similares